Table 3.

Selected dendritic cell vaccine trials

Trial Name (Acronym)	Trial ID	Phase	Design	Criteria	Arms	Primary Outcome	Number of Patients	Results Expected	Status
Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma	NCT02010606	I	Non‐randomized, open‐label, parallel assignment	Age ≥18 y, Newly diagnosed GB, KPS ≥70	DC Vaccine + SOC vs DC Vaccine ± bevacizumab	Safety, tolerability, # of adverse events	40	2021	Active, Not Recruiting
Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme (ATTAC‐II)	NCT02465268	II	Randomized, parallel assignment, single	Age ≥18 y, Newly diagnosed supratentorial GB, KPS ≥70	pp65‐shLAMP DC + GM‐CSF + Td vs pp65‐flLAMP DC + GM‐CSF + Td vs Placebo	Change in median OS	120	2024	Recruiting
Dendritic Cell Vaccine for Patients With Brain Tumors	NCT01204684	II	Randomized, parallel assignment, open‐label	Age 18‐70 y, Recurrent AA, AO, GB, KPS > 60	DC + Placebo vs DC + resiquimod vs DC + adjuvant polyICLC	Most effective combination of DC vaccine components	60	2021	Active, Not Recruiting
Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma	NCT03400917	II	Single‐arm, open label	Age 18‐70 y, KPS 70‐100, Successful establishment of autologous stem cell line, Plans to begin adjuvant therapy	DC Vaccine (AV‐GBM‐1) + GM‐CSF	OS	55	2023	Recruiting

Abbreviations: AA, anaplastic astrocytoma; AO, anaplastic oligodendroglioma; DC, dendritic cells; GB, glioblastoma; GM‐CSF, granulocyte‐macrophage colony stimulating factor; GTR, gross total resection; KPS, Karnofsky Performance Status; LE, life expectancy; MGMT, O6‐methylguanine‐DNA methyltransferase; OS, overall survival; PARP, poly‐ADP ribose polymerase; PD‐1, programmed‐death 1; PFS, progression‐free survival; RT, radiotherapy; SOC, standard of care; TMZ, temozolomide.